Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4883MR)

This product GTTS-WQ4883MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4883MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10446MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ13476MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ14397MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ2796MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ6642MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ704MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ14113MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ3149MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW